Nissay Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.46M | Buy |
29,762
+3,476
| +13% | +$640K | 0.03% | 302 |
|
|
2025
Q4 | $4.63M | Sell |
26,286
-19,186
| -42% | -$3.13M | 0.02% | 331 |
|
|
2025
Q3 | $6.37M | Buy |
45,472
+654
| +1% | +$88.4K | 0.04% | 279 |
|
|
2025
Q2 | $5.63M | Sell |
44,818
-2,386
| -5% | -$297K | 0.03% | 302 |
|
|
2025
Q1 | $6.46M | Buy |
47,204
+3,325
| +8% | +$475K | 0.04% | 273 |
|
|
2024
Q4 | $6.64M | Buy |
43,879
+1,379
| +3% | +$233K | 0.04% | 272 |
|
|
2024
Q3 | $8.24M | Buy |
42,500
+2,592
| +6% | +$542K | 0.05% | 240 |
|
|
2024
Q2 | $9.25M | Buy |
39,908
+7,563
| +23% | +$1.64M | 0.06% | 197 |
|
|
2024
Q1 | $6.97M | Buy |
32,345
+12,901
| +66% | +$3.02M | 0.05% | 237 |
|
|
2023
Q4 | $5.03M | Buy |
19,444
+1,763
| +10% | +$433K | 0.04% | 251 |
|
|
2023
Q3 | $4.54M | Buy |
17,681
+1,319
| +8% | +$353K | 0.04% | 256 |
|
|
2023
Q2 | $4.66M | Sell |
16,362
-51
| -0.3% | -$15.2K | 0.04% | 251 |
|
|
2023
Q1 | $4.56M | Sell |
16,413
-617
| -4% | -$171K | 0.04% | 251 |
|
|
2022
Q4 | $4.72M | Sell |
17,030
-202
| -1% | -$57.1K | 0.05% | 240 |
|
|
2022
Q3 | $4.6M | Buy |
17,232
+566
| +3% | +$120K | 0.05% | 223 |
|
|
2022
Q2 | $3.4M | Buy |
16,666
+54
| +0.3% | +$11K | 0.03% | 289 |
|
|
2022
Q1 | $3.5M | Buy |
16,612
+162
| +1% | +$35.2K | 0.03% | 332 |
|
|
2021
Q4 | $3.95M | Sell |
16,450
-974
| -6% | -$250K | 0.03% | 324 |
|
|
2021
Q3 | $4.93M | Buy |
17,424
+367
| +2% | +$120K | 0.04% | 249 |
|
|
2021
Q2 | $5.91M | Sell |
17,057
-1,510
| -8% | -$457K | 0.05% | 212 |
|
|
2021
Q1 | $5.19M | Sell |
18,567
-749
| -4% | -$202K | 0.05% | 213 |
|
|
2020
Q4 | $4.73M | Sell |
19,316
-947
| -5% | -$244K | 0.07% | 203 |
|
|
2020
Q3 | $5.75M | Sell |
20,263
-4,268
| -17% | -$1.19M | 0.1% | 172 |
|
|
2020
Q2 | $6.56M | Sell |
24,531
-97
| -0.4% | -$29.2K | 0.13% | 164 |
|
|
2020
Q1 | $7.79M | Buy |
24,628
+50
| +0.2% | +$15.2K | 0.2% | 114 |
|
|
2019
Q4 | $7.29M | Sell |
24,578
-1,551
| -6% | -$430K | 0.16% | 154 |
|
|
2019
Q3 | $6.08M | Buy |
26,129
+693
| +3% | +$161K | 0.15% | 162 |
|
|
2019
Q2 | $5.95M | Sell |
25,436
-389
| -2% | -$89.8K | 0.15% | 159 |
|
|
2019
Q1 | $6.11M | Sell |
25,825
-601
| -2% | -$189K | 0.16% | 157 |
|
|
2018
Q4 | $7.95M | Sell |
26,426
-805
| -3% | -$257K | 0.24% | 95 |
|
|
2018
Q3 | $9.62M | Buy |
27,231
+483
| +2% | +$166K | 0.26% | 93 |
|
|
2018
Q2 | $7.76M | Buy |
26,748
+1,543
| +6% | +$434K | 0.23% | 110 |
|
|
2018
Q1 | $6.9M | Sell |
25,205
-982
| -4% | -$305K | 0.22% | 115 |
|
|
2017
Q4 | $8.34M | Buy |
+26,187
| New | +$8.4M | 0.25% | 97 |
|
Other funds holding BIIB
VCM
VPM
Nissay Asset Management's BIIB Position: Q1 2026 in Review
Nissay Asset Management increased its Biogen (BIIB) stake by 13% in Q1 2026, buying an estimated $640K and bringing the position to 29,762 shares worth $5.46M. The position accounts for 0.03% of the portfolio, ranked #302.
Nissay Asset Management first reported a position in BIIB in Q4 2017 and has held it in 34 quarters since. The position peaked at $9.62M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Nissay Asset Management held 29,762 shares of Biogen worth $5.46M as of Q1 2026.
- Nissay Asset Management bought 3,476 Biogen shares in Q1 2026, an estimated $640K.
- Biogen made up 0.03% of Nissay Asset Management's portfolio in Q1 2026, its #302 holding.
- Nissay Asset Management first reported a position in Biogen in Q4 2017 and has held it in 34 quarters since.
- Nissay Asset Management's Biogen position peaked at $9.62M in Q3 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Nissay Asset Management's 13F filing for Q1 2026, filed 15 May 2026.